A single-center retrospective study assessing the cardiotoxicity and its management in metastatic Non-small cell lung cancer patients treated with tyrosine kinase inhibitors
Latest Information Update: 20 Jul 2022
At a glance
- Drugs Afatinib (Primary) ; Alectinib (Primary) ; Brigatinib (Primary) ; Crizotinib (Primary) ; Dabrafenib (Primary) ; Entrectinib (Primary) ; Osimertinib (Primary) ; Trametinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 20 Jul 2022 New trial record
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology